Recognition and testing for ROS1 rearrangements in non-small cell lung cancer (NSCLC) have significantly advanced in recent years. Initially, ROS1 was...

Janus kinase 1 (JAK1) inhibitors showed potential superior efficacy vs anti–IL-13 antibodies among 75 patients receiving treatment for moderate to sev...

ABSTRACT Objectives: To understand the perceptions of patients and primary care physicians as well as barriers to and facilitators of engaging with a...

The treatment of non–small cell lung cancer (NSCLC) harboring EGFR mutations has transformed with the introduction of targeted therapies. Despite the...

Today, the FDA approved selumetinib (Koselugo; AstraZeneca) in both granule and capsule forms for pediatric patients as young as 1 year old with neuro...

Durable and significant improvements in survival outcomes were seen at 5 years of follow-up among patients with non-small cell lung cancer (NSCLC) usi...

In the second part of her Q&A, Kathy Oubre, MS, discusses the recent updates surrounding the most favored nation (MFN) executive order, including how...

In this second part of a 2-part Q&A, Doree L. Rossey, BS, PHDHP, RDH, a public health dental hygiene practitioner and dental care manager supervisor,...

The FDA has announced a crackdown on false or misleading drug advertisements by issuing thousands of letters instructing pharmaceutical companies to c...

ABSTRACT Objectives: The cost and quality problems of health care in the US have been aggravated by separate silos for research and care delivery that...